Article
Stromal ColXα1 expression correlates with tumor-infiltrating lymphocytes and predicts adjuvant therapy outcome in ER-positive/HER2-positive breast cancer.
BMC cancer - 1 Nov 2019
Zhao Chaohui Lisa, Singh Kamaljeet, Brodsky Alexander S, Lu Shaolei, Graves Theresa A, Fenton Mary Anne, Yang Dongfang, Sturtevant Ashlee, Resnick Murray B, Wang Yihong
Abstract excerpt
BACKGROUND: The breast cancer microenvironment contributes to tumor progression and response to chemotherapy. Previously, we reported that increased stromal Type X collagen α1 (ColXα1) and low TILs correlated with poor pathologic response to neoadjuvant therapy in estrogen receptor and HER2-positive (ER+/HER2+) breast cancer. Here, we investigate the relationship of ColXα1 and long-term outcome of ER+/HER2+...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.
